It appears that the major defects in the mouse are not in normal development; but rather in subsequent plastic changes: the mouse seems to be incapable of sustaining neovascularisation, for example, which may make AnxA2 a promising target for drug intervention in cancer treatment. This evidence concerns the gene ANXA2 and cancer.